These findings directly support clinical investigation of SUR1-TRPM4 inhibitors as potential anti-seizure therapies in epilepsy patients and suggest further investigations into the contribution of SUR1-TRPM4 to seizures induced by specific epileptogenic insults, such as traumatic brain injury (TBI), are warranted. This evidence concerns the gene TRPM4 and epilepsy.